Bayer’s ASSESS study is a randomised, double-blind, placebo-controlled, parallel group phase 2a trial with an extension phase ...

Johnson & Johnson has received European Commission approval for nipocalimab, marketed as IMAAVY, as an add-on therapy for ...

The phase 1 trial, VNA-318-01, was a randomized, double-blind study involving 92 healthy male subjects. Interim results ...

Pharvaris has announced positive topline data from its RAPIDe-3 pivotal phase 3 study, confirming the potential of ...

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending Amvuttra ...

Xmoor Pharma and Royal Free London NHS Foundation Trust have announced a strategic collaboration to create a seamless pathway ...

Young people are our future workforce, so it’s important that companies have a youth-positive culture. To be competitive, ...

Merck Sharp & Dohme (MSD) has agreed to acquire Cidara Therapeutics in a transaction valued at approximately $9.2 billion, ...

Bayer has reported encouraging topline findings from its global phase 3 OCEANIC-STROKE study, evaluating the investigational ...

SERB Pharmaceuticals has appointed Dr Vignesh Rajah as its new Chief Medical Officer, bringing over 20 years of global ...

Draig Therapeutics has announced the appointment of Ivana Magovčević-Liebisch as President and Chief Executive Officer. She ...

The Academy of Medical Sciences and Wellcome have announced a new five-year agreement worth £27.3 million, reinforcing their ...